Literature DB >> 23733660

Localized encapsulating peritoneal sclerosis constricting the terminal ileum--an unusual appearance requiring surgical intervention.

Sayed M Habib1, Sander M Hagen, Mario R Korte, Robert Zietse, Frank J M F Dor, Michiel G H Betjes.   

Abstract

BACKGROUND: Encapsulating peritoneal sclerosis (EPS) is a rare complication of peritoneal dialysis (PD). It is characterized by encapsulation of the bowel, causing symptoms of intestinal obstruction. Exclusive involvement of parts of the bowel may occur and may be more common than previously thought. Our main objective was to investigate and report on patients with localized EPS.
METHODS: Between July 2002 and December 2011, 9 of 17 EPS patients were referred to our department of surgery for a diagnostic laparotomy. Three of the 9 cases showed localized encapsulation of the small bowel and were selected for the purpose of this study.
RESULTS: All 3 patients presented with an acute inflammatory state and symptoms of bowel obstruction. In 2 patients, EPS became clinically overt after kidney transplantation; the third patient was diagnosed while on hemodialysis. All shared a history of PD ranging from 31 to 101 months. In none of the patients was radiologic examination conclusive, although 2 showed peritoneal thickening and ascites. Each patient underwent laparotomy, confirming EPS. In all cases, a thickened peritoneal membrane became apparent, predominantly covering the ileocecal region of the intestine. In addition, a constrictive membrane at the level of the terminal ileum was noted. In 2 cases, the patients underwent enterolysis and dissection of the constricting fibrotic peritoneal membrane (peritonectomy) without bowel resection. The 3rd patient was managed with parenteral nutrition and tamoxifen. The postoperative course in 1 patient was complicated by infected ascites that resolved with antibiotic treatment. Eventually, all patients were doing well, with adequate oral intake and without the need for repeat surgery.
CONCLUSIONS: Localized EPS may be more common than previously thought. It has a predilection for the level of the terminal ileum. We believe that an elective diagnostic laparotomy should be considered early, because this procedure offers both diagnostic opportunities and therapeutic options. Localized EPS cases may benefit most from enterolysis and peritonectomy.

Entities:  

Keywords:  Localized EPS; laparotomy; terminal ileum

Mesh:

Year:  2013        PMID: 23733660      PMCID: PMC3797668          DOI: 10.3747/pdi.2012.00105

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  11 in total

1.  Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen.

Authors:  Mohmed A Eltoum; Sue Wright; Julian Atchley; Juan C Mason
Journal:  Perit Dial Int       Date:  2006 Mar-Apr       Impact factor: 1.756

2.  Seventeen years' experience of surgical options for encapsulating peritoneal sclerosis.

Authors:  Hideki Kawanishi; Sadanori Shintaku; Misaki Moriishi; Kiyohiko Dohi; Shinichiro Tsuchiya
Journal:  Adv Perit Dial       Date:  2011

Review 3.  Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment.

Authors:  S M Habib; M G H Betjes; M W J A Fieren; E W Boeschoten; A C Abrahams; W H Boer; D G Struijk; W Ruger; C Krikke; R Westerhuis; R G L de Sévaux; F M van der Sande; A Gaasbeek; M R Korte
Journal:  Neth J Med       Date:  2011 Nov-Dec       Impact factor: 1.422

4.  Pathology of encapsulating peritoneal sclerosis.

Authors:  Kazuho Honda; Hideaki Oda
Journal:  Perit Dial Int       Date:  2005-04       Impact factor: 1.756

Review 5.  Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences.

Authors:  Steven Guest
Journal:  Perit Dial Int       Date:  2009 May-Jun       Impact factor: 1.756

6.  Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis.

Authors:  Eric F H van Bommel; Tadek R Hendriksz; Antonius W L C Huiskes; Antoine G M Zeegers
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

7.  Risk factors associated with encapsulating peritoneal sclerosis in Dutch EPS study.

Authors:  Mario R Korte; Denise E Sampimon; Hester F Lingsma; Marien W Fieren; Caspar W N Looman; Robert Zietse; Willem Weimar; Michiel G H Betjes
Journal:  Perit Dial Int       Date:  2011-03-31       Impact factor: 1.756

Review 8.  Encapsulating peritoneal sclerosis: the state of affairs.

Authors:  Mario R Korte; Denise E Sampimon; Michiel G H Betjes; Raymond T Krediet
Journal:  Nat Rev Nephrol       Date:  2011-08-02       Impact factor: 28.314

9.  Tamoxifen is associated with lower mortality of encapsulating peritoneal sclerosis: results of the Dutch Multicentre EPS Study.

Authors:  Mario R Korte; Marien W Fieren; Denise E Sampimon; Hester F Lingsma; Willem Weimar; Michiel G H Betjes
Journal:  Nephrol Dial Transplant       Date:  2010-06-27       Impact factor: 5.992

10.  Assessing the validity of an abdominal CT scoring system in the diagnosis of encapsulating peritoneal sclerosis.

Authors:  Ruth M Tarzi; Adrian Lim; Steven Moser; Sohail Ahmad; Abraham George; Gowrie Balasubramaniam; Elaine J Clutterbuck; Wladyslaw Gedroyc; Edwina A Brown
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

View more
  3 in total

1.  Classification of encapsulating peritoneal sclerosis is important, but must encapsulate the entire spectrum of the disease.

Authors:  Christopher J E Watson; Andrew J Butler; J Andrew Bradley
Journal:  Perit Dial Int       Date:  2013 Sep-Oct       Impact factor: 1.756

2.  Case report: acute bowel obstruction with an isolated transition point in peritoneal dialysis patients; a presentation of encapsulating peritoneal sclerosis?

Authors:  Sassan Ghazan-Shahi; Joanne M Bargman
Journal:  BMC Nephrol       Date:  2016-01-05       Impact factor: 2.388

3.  Post-transplantation encapsulating peritoneal sclerosis without inflammation or radiological abnormalities.

Authors:  Sayed Meelad Habib; Frank Johan Marinus Frederik Dor; Mario Richard Korte; Sander Martijn Hagen; Michiel Gerardus Henricus Betjes
Journal:  BMC Nephrol       Date:  2013-09-26       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.